* Says drug is well-tolerated
* Says no treatment-related adverse events
* Shares up 12 pct in pre-market trade
Oct 21 (Reuters) - Biopharmaceutical company CombinatoRx Inc CRXX.O said its knee osteoarthritis drug, Synavive, continued to show efficacy in a mid-stage 12-month extension trial, sending its shares up 12 percent in pre-market trade.
“Synavive appears to be well-tolerated and efficacious in reducing the signs and symptoms of knee osteoarthritis over a 3 to 12-month period,” interim CEO Robert Forrester said.
In the extension trial for Synavive, there was no treatment-related adverse events, the company said.
Shares of the Cambridge, Massachusetts-based company were up at $1.49 in pre-market trade. They had closed at $1.33 Tuesday on Nasdaq. (Reporting by Anuradha Ramanathan in Bangalore; Editing by Himani Sarkar)